|
2018 Conference Publication Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study)Inshasi, Jihad Said, Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Vermersch, Patrick and Margolin, David H. (2018). Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study). 3rd Congress of Middle East North Africa Committee for Research and Treatment in Multiple Sclerosis (MENACTRIMS), Dubai, UAE, 24-25 November 2017 . London, United Kingdom : Sage Publications. |
|
2018 Journal Article Patient with ALS with a novel TBK1 mutation, widespread brain involvement, behaviour changes and metabolic dysfunctionMcCombe, Pamela A., Ngo, Shyuan T., Guo, Christine Cong, Fazlollahi, Amir, Bollmann, Saskia, Wang, Liting, Hu, Xintao, Barth, Markus, Salvado, Olivier, Davis, Mark, Ceslis, Amelia, Robinson, Gail, Henderson, Robert D. and Steyn, Frederik J. (2018). Patient with ALS with a novel TBK1 mutation, widespread brain involvement, behaviour changes and metabolic dysfunction. Journal of Neurology, Neurosurgery and Psychiatry, 90 (8), 952-954. doi: 10.1136/jnnp-2018-318823 |
|
2018 Conference Publication Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study)McCombe, Pamela, Boyko, Alexey N., DeSeze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Vermersch, Patrick, Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study). Annual Scientific Meeting of the Australian-and-New Zealand-Association-of-Neurologists (ANZAN), Darwin Australia, May 29 - June 1 2018. London, United Kingdom: B M J Group. doi: 10.1136/jnnp-2018-ANZAN.43 |
|
2018 Conference Publication Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study)Vermersch, Patrick, Coles, Alasdair J., Boyko, Alexey N., De Seze, Jerome, Hartung, Hans-Peter, Havrdova, Eva, Inshasi, Jihad Said, McCombe, Pamela, Montalban, Xavier, Pozzilli, Carlo, Selmaj, Krzysztof W., Margolin, David H., Melanson, Maria, Daizadeh, Nadia, Rodriguez, Claudio E. and Van Wijmeersch, Bart (2018). Durable Clinical Efficacy of Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS I Patients (TOPAZ Study). 70th Annual Meeting of the American-Academy-of-Neurology (AAN), Los Angeles, CA, United States, Apr 21-27, 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins. |
|
2018 Conference Publication Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study)Van Wijmeersch, B., Vermersch, P., Boyko, A., de Seze, J., Hartung, H. -P., Havrdova, E. Kubala, Inshasi, J. Said, McCombe, P., Montalban, X., Pozzili, C., Melanson, M., Daizadeh, N., Rodriguez, C. and Selmaj, K. (2018). Alemtuzumab provides durable clinical efficacy in patients with active rrms in the absence of continuous treatment: 7-Year follow-up of CARE-MS I (TOPAZ Study). 4th Congress of the European Academy of Neurology (EAN), Lisbon, Portugal, 16-19 June 2018. Chichester, West Sussex, United Kingdom: Wiley-Blackwell. |
|
2017 Journal Article Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosisBenyamin, Beben, He, Ji, Zhao, Qiongyi, Gratten, Jacob, Garton, Fleur, Leo, Paul J., Liu, Zhijun, Mangelsdorf, Marie, Al-Chalabi, Ammar, Anderson, Lisa, Butler, Timothy J., Chen, Lu, Chen, Xiang-Ding, Cremin, Katie, Deng, Hong-Weng, Devine, Matthew, Edson, Janette, Fifita, Jennifer A., Furlong, Sarah, Han, Ying-Ying, Harris, Jessica, Henders, Anjali K., Jeffree, Rosalind L., Jin, Zi-Bing, Li, Zhongshan, Li, Ting, Li, Mengmeng, Lin, Yong, Liu, Xiaolu ... Fan, Dongsheng (2017). Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis. Nature Communications, 8 (1) 611, 611. doi: 10.1038/s41467-017-00471-1 |
|
2017 Journal Article Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMSLorscheider, Johannes, Jokubaitis, Vilija G., Spelman, Tim, Izquierdo, Guillermo, Lugaresi, Alessandra, Havrdova, Eva, Horakova, Dana, Trojano, Maria, Duquette, Pierre, Girard, Marc, Prat, Alexandre, Grand'Maison, Francois, Grammond, Pierre, Pucci, Eugenio, Boz, Cavit, Sola, Patrizia, Ferraro, Diana, Spitaleri, Daniele, Lechner-Scott, Jeanette, Terzi, Murat, Van Pesch, Vincent, Iuliano, Gerardo, Bergamaschi, Roberto, Ramo-Tello, Cristina, Granella, Franco, Oreja-Guevara, Celia, Butzkueven, Helmut, Kalincik, Tomas, MSBase Study Group and McCombe, Pamela A. (2017). Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS. Neurology, 89 (10), 1050-1059. doi: 10.1212/WNL.0000000000004330 |
|
2017 Journal Article Towards personalized therapy for multiple sclerosis: prediction of individual treatment responseKalincik, Tomas, Manouchehrinia, Ali, Sobisek, Lukas, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Girard, Marc, Prat, Alexandre, Duquette, Pierre, Grammond, Pierre, Sola, Patrizia, Hupperts, Raymond, Grand'Maison, Francois, Pucci, Eugenio, Boz, Cavit, Alroughani, Raed, Van Pesch, Vincent, Lechner-Scott, Jeannette, Terzi, Murat, Bergamaschi, Roberto, Iuliano, Gerardo, Granella, Franco, Spitaleri, Daniele, Shaygannejad, Vahid, Oreja-Guevara, Celia ... Butzkueven, Helmut (2017). Towards personalized therapy for multiple sclerosis: prediction of individual treatment response. Brain, 140 (9), 2426-2443. doi: 10.1093/brain/awx185 |
|
2017 Journal Article Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosisKalincik, Tomas, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Lechner-Scott, Jeannette, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Solaro, Claudio, Grand'Maison, Francois, Hupperts, Raymond, Prevost, Julie, Sola, Patrizia, Ferraro, Diana, Terzi, Murat, Butler, Ernest, Slee, Mark, Kermode, Allan, Fabis-Pedrini, Marzena, McCombe, Pamela, Barnett, Michael, Shaw, Cameron, Hodgkinson, Suzanne, Butzkueven, Helmut and MSBase Study Group (2017). Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis. Multiple Sclerosis (Houndmills, Basingstoke, England), 24 (12), 1352458517728812-1626. doi: 10.1177/1352458517728812 |
|
2017 Journal Article Incidence and prevalence of NMOSD in Australia and New ZealandBukhari, Wajih, Prain, Kerri M., Waters, Patrick, Woodhall, Mark, O'Gorman, Cullen M., Clarke, Laura, Silvestrini, Roger A., Bundell, Christine S., Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce J., Brown, Matthew, Brownlee, Wallace J., Butzkueven, Helmut, Carroll, William M., Chen, Celia, Coulthard, Alan, Dale, Russell C., Das, Chandi, Dear, Keith, Fabis-Pedrini, Marzena J., Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert, Henderson, Andrew P. D. ... Broadley, Simon A. (2017). Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology Neurosurgery and Psychiatry, 88 (8), 632-638. doi: 10.1136/jnnp-2016-314839 |
|
2017 Journal Article Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventionsNgo, Shyuan T., Mi, Jia D., Henderson, Robert D., McCombe, Pamela A. and Steyn, Frederik J. (2017). Exploring targets and therapies for amyotrophic lateral sclerosis: current insights into dietary interventions. Degenerative Neurological and Neuromuscular Disease, 7, 95-108. doi: 10.2147/DNND.S120607 |
|
2017 Journal Article Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohortGarton, Fleur C., Benyamin, Beben, Zhao, Qiongyi, Liu, Zhijun, Gratten, Jacob, Henders, Anjali K., Zhang, Zong-Hong, Edson, Janette, Furlong, Sarah, Morgan, Sarah, Heggie, Susan, Thorpe, Kathryn, Pfluger, Casey, Mather, Karen A., Sachdev, Perminder S., McRae, Allan F., Robinson, Matthew R., Shah, Sonia, Visscher, Peter M., Mangelsdorf, Marie, Henderson, Robert D., Wray, Naomi R. and McCombe, Pamela A. (2017). Whole exome sequencing and DNA methylation analysis in a clinical amyotrophic lateral sclerosis cohort. Molecular Genetics and Genomic Medicine, 5 (4), 418-428. doi: 10.1002/mgg3.302 |
|
2017 Journal Article Predictions of resting energy expenditure in amyotrophic lateral sclerosis are greatly impacted by reductions in fat free massIoannides, Z. A., Steyn, F. J., Henderson, R. D., McCombe, P. A. and Ngo, S. T. (2017). Predictions of resting energy expenditure in amyotrophic lateral sclerosis are greatly impacted by reductions in fat free mass. Cogent Medicine, 4 (1), 1343000. doi: 10.1080/2331205X.2017.1343000 |
|
2017 Journal Article Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneityMcCombe, P. A., Wray, N. R. and Henderson, R. D. (2017). Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity. Expert Review of Neurotherapeutics, 17 (6), 561-577. doi: 10.1080/14737175.2017.1273772 |
|
2017 Journal Article Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survivalXu, Zhouwei, Alruwaili, Ashwag Rafea S., Henderson, Robert David and McCombe, Pamela Ann (2017). Screening for cognitive and behavioural impairment in amyotrophic lateral sclerosis: frequency of abnormality and effect on survival. Journal of the Neurological Sciences, 376, 16-23. doi: 10.1016/j.jns.2017.02.061 |
|
2017 Conference Publication Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I)Singer, Barry, Coles, Alasdair J., Boyko, Alexey N., Cohen, Jeffrey A., De Seze, Jérôme, Fox, Edward J., Havrdova, Eva, Hartung, Hans-Peter, Inshasi, Jihad Said, McCombe, Pamela, Selmaj, Krzysztof W., Vermersch, Patrick, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio and Montalban, Xavier (2017). Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I). AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.s24.005 |
|
2017 Conference Publication Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-upOreja-Guevara, Celia, Alroughani, Raed, Brassat, David, Boyko, Alexey N., McCombe, Pamela, Steingo, Brian, Van Wijmeersch, Bart, Margolin, David H., Thangavelu, Karthinathan, Rodriguez, Claudio E., Vermersch, Patrick and on behalf of the CARE-MS I and CAMMS03409 Investigators (2017). Durable Improvement in Clinical Outcomes in Patients With Relapsing-Remitting Multiple Sclerosis Who Discontinued SC IFNB-1a and Initiated Alemtuzumab: CARE-MS I Extension Study 4-Year Follow-up. AAN 69th Annual Meeting, Boston, MA United States, 22-28 April 2017. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.88.16_supplement.p5.360 |
|
2017 Journal Article Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort studyKalincik, Tomas, Brown, J. William L., Robertson, Neil, Willis, Mark, Scolding, Neil, Rice, Claire M., Wilkins, Alastair, Pearson, Owen, Ziemssen, Tjalf, Hutchinson, Michael, McGuigan, Christopher, Jokubaitis, Vilija, Spelman, Tim, Horakova, Dana, Havrdova, Eva, Trojano, Maria, Izquierdo, Guillermo, Lugaresi, Alessandra, Prat, Alexandre, Girard, Marc, Duquette, Pierre, Grammond, Pierre, Alroughani, Raed, Pucci, Eugenio, Sola, Patrizia, Hupperts, Raymond, Lechner-Scott, Jeannette, Terzi, Murat, Van Pesch, Vincent ... Grp, MSBase Study (2017). Treatment effectiveness of alemtuzumab compared with natalizumab, fingolimod, and interferon beta in relapsing-remitting multiple sclerosis: a cohort study. Lancet Neurology, 16 (4), 271-281. doi: 10.1016/S1474-4422(17)30007-8 |
|
2017 Journal Article Anthropometric measures are not accurate predictors of fat mass in ALSIoannides, Zara A., Steyn, Frederik J., Henderson, Robert D., Mccombe, Pamela A. and Ngo, Shyuan T. (2017). Anthropometric measures are not accurate predictors of fat mass in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 18 (7-8), 486-491. doi: 10.1080/21678421.2017.1317811 |
|
2017 Conference Publication Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosisMerkel, B., Jokubaitis, V., Spelman, T., Horakova, D., Havrdova, E., Trojano, M., Izquierdo, G., Lugaresi, A., Prat, A., Girard, M., Duquette, P., Sola, P., Ferraro, D., Grammond, P., Hupperts, R., Bergamaschi, R., Alroughani, R., Boz, C., Terzi, M., Pucci, E., Van Pesch, V., Grand'Maison, F., Fernandez-Bolanos, R., Lechner-Scott, J., Spitaleri, D., Shaygannejad, V., Iuliano, G., Granella, F., Solaro, C. ... Kalincik, T. (2017). Timing of high-efficacy disease modifying therapies for relapsing-remitting multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications. doi: 10.1177/1352458517731283 |
